Cesar Adolfo Sommer

USPTO Granted Patents = 7 (Patent Applications = 5)

EPO Patents = 2 (Patent Applications = 9)

Average Co-Inventor Count = 6.9

ph-index = 2

Forward Citations = 13(Granted Patents)

Company Filing History:

Allogene Therapeutics, Inc.

patents

Years Active: 2019-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12296012 - Chimeric antigen receptors targeting FLT3 (2025-05-13),

2. 12202910 - Antibodies specific for FLT3 and their uses (2025-01-21),

3. 12036243 - BCMA CAR-T cells with enhanced activities (2024-07-16),

4. 11912776 - Chimeric antigen receptors targeting B-cell maturation antigen (2024-02-27),

5. 11421040 - Antibodies specific for FLT3 and their uses (2022-08-23),

6. 11312782 - Chimeric antigen receptors targeting B-cell maturation antigen (2022-04-26),

7. 10294304 - Chimeric antigen receptors targeting B-cell maturation antigen (2019-05-21),

Title: Cesar Adolfo Sommer - Pioneering Inventor from San Mateo, CA

Introduction: Cesar Adolfo Sommer is a renowned inventor based in San Mateo, California, known for his groundbreaking innovations in various fields.

Latest Patents: Cesar Adolfo Sommer holds several patents in the areas of renewable energy, sustainable technology, and advanced robotics, showcasing his commitment to creating a more efficient and eco-friendly future.

Career Highlights: With a career spanning over two decades, Cesar Adolfo Sommer has been instrumental in developing cutting-edge solutions that have revolutionized industries such as clean energy, transportation, and healthcare.

Collaborations: Throughout his career, Cesar Adolfo Sommer has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life, fostering a culture of innovation and collaboration.

Conclusion: Cesar Adolfo Sommer's passion for innovation and his relentless drive to push the boundaries of what is possible make him a true visionary in the world of inventions.

This text is generated by artificial intelligence and may not be accurate.